Medical Group
Competitive Advantages
- Over a century of knowledge in the medical field and partnerships with healthcare professionals
- Canon’s diverse range of proprietary imaging and manufacturing technologies
- Global sales/service network over 150 countries/regions
Basic Rationale on Value Creation
Amid global trends of rapidly aging populations, rising
healthcare costs and the ongoing infectious threat
posed by COVID-19, demand for healthcare has risen to
unprecedented levels, and promoting better health
while preventing disease is now a common challenge
across countries and regions worldwide. Under such
conditions, Canon’s Medical Group is engaged in
business that respects a shared set of values with
patients and healthcare professionals. In terms of value
creation, the foremost priority for Canon is to work out
what kinds of technology are required to fulfill the
needs of those providing healthcare; to supply the
technology for realizing this practically; and to find ways
of ensuring ease-of-use and maximizing economic
value. These ideas are summarized in the Canon
Medical management slogan Made for Life, which plays
a guiding role in the Medical Group.
The Medical Group is mainly focused on the three
fields of diagnostic imaging, healthcare IT and in vitro
diagnostics. Our products and services help to prevent
disease, maintain people’s health, and contribute to
recovery from illness in varied ways. In the field of
diagnostic imaging, we are utilizing AI technology to
develop CT, MRI, and PET-CT image reconstruction
technology that offers higher image quality while
reducing radiation dose and noise, and to realize
easy-to-operate diagnostic ultrasound systems that
allow more efficient testing. In healthcare IT, we are
developing IT solutions to collect, integrate, analyze and
process different types of diagnostic images and data.
In the field of in vitro diagnostics (IVD), we are supplying
rapid genetic testing systems, antigen test kits and IVD
reagents for COVID-19 testing.
These business activities are directly involved with
solving social issues related to human health and
welfare, thus contributing to achieving the SDGs,
most notably SDG 3 (Good Health and Wellbeing),
SDG 9 (Industry, Innovation and Infrastructure),
and SDG 17 (Partnerships for the Goals).
Related SDGs

- 3.d By incorporating image reconstruction technology
developed using AI, we have brought to market
diagnostic imaging equipment that achieves high
image quality while reducing radiation dose compared
to conventional CT scanners.

- 9.5 Canon’s efforts to promote innovation include joint
research projects with the National Cancer Center of
Japan in the field of photon-counting CT systems, and
with Kyoto University’s Center for iPS Cell Research and
Application to develop high-quality iPS cell lines for
autograft use.

- 17.6 Through partnerships with universities and
medical institutions in Japan and overseas, we are
carrying out leading-edge research on AI-based
precision care approaches, including the latest clinical
research on CT, MRI, and diagnostic ultrasound systems.
Business Strategy in Phase VI
Business opportunities
- Harnessing new materials to create additional value in
diagnostic imaging equipment
- Advances in genetic and other biotech fields and
regenerative medicine
- Adoption of ways to promote and demonstrate systems
remotely using DX tools
Risks
- Reduced opportunities for sales and supply chain disruption
caused by the COVID-19 pandemic
- Preferential policies for locally manufactured products for
medical devices
- Underdeveloped presence in the U.S., the market with the
greatest global influence
Issues
- Expansion of business portfolio beyond diagnostic imaging systems
- Gaining market share in the U.S. and elsewhere for diagnostic imaging
equipment and upgrading global presence
- Improving the supply chain by switching to readily accessible materials and
alternatives in response to changes in the environment
Initiatives for Year I of Phase VI (2021)
- Our efforts to commercialize photon-counting CT systems, which are expected to achieve high image resolution
while reducing radiation dose compared with conventional CT scanners, included the acquisition of Redlen
Technologies and the start of a related joint research project with the National Cancer Center of Japan.
- Product launches included a digital X-ray system for multipurpose scans; a digital PET-CT system using AI-based
image reconstruction technology; a 320-row area detector CT scanner; a high-power 1.5-tesla MRI scanner; and new
premium-class diagnostic ultrasound systems that support highly efficient testing.
- We established a global organizational structure to strengthen the healthcare IT business and sought to speed up
joint research with medical institutions.
Strategic Focus for Phase VI Going Forward (through 2025)
- Further expansion of diagnostic imaging business through external partnerships or M&A
- Expand portfolio into fields beyond diagnostic imaging, such as IVD reagents and healthcare IT
In diagnostic imaging, we will develop technology to facilitate commercialization of photon-counting CT systems
that have the potential to deliver ultra-high image quality while significantly reducing radiation dose required in
scanning. In addition, we are developing next-generation high-performance MRI scanning systems by combining
technologies from Group companies, notably the RF coil technology of QED, with image-processing technology
based on AI. In ultrasound equipment, we are working on cutting the cost of sales via in-house production of a
common platform using proprietary technology.
To develop businesses beyond diagnostic imaging, we are working to develop healthcare IT systems that gather,
integrate, and analyze image and non-image data collected in clinical settings. In the IVD field, we are working to
expand Canon’s business portfolio by broadening our presence into areas such as peripheral devices used in testing.